News Alkermes bets $2.1bn on Avadel and its narcolepsy drug Alkermes will buy Avadel Pharma and its fast-growing narcolepsy drug Lumryz in a deal valued at up to $2.1 billion.
News Ipsen buys ImCheck, adding mid-stage leukaemia drug Ipsen has agreed to buy ImCheck and its anti-BTN3A antibody for acute myeloid leukaemia in a deal that could be worth up to €1bn.
News Merck looking to rare disease deals to build health momentum Germany's Merck KGaA is looking at making further acquisitions to boost its business, with a focus on life sciences and rare diseases.
News Bavarian Nordic urges investors to accept takeover offer A private equity investment consortium has raised a takeover offer for Denmark's Bavarian Nordic, but some shareholders are still reluctant to sell.
News J&J streamlines with plan to hive off orthopaedics unit Johnson & Johnson has said it wants to spin off its orthopaedics division as part of an effort to redirect its business towards higher-growth areas.
News BMS builds in 'in vivo' cell therapy with $1.5bn Orbital buy Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics, a developer of in vivo cell therapies, for $1.5bn in cash.
News Beacon's XLRP gene therapy set for filing after phase 3 win Beacon is preparing to file for approval of its gene therapy for X-linked retinitis pigmentosa, after reporting encouraging phase 3 data.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
